Literature DB >> 19349491

Emerging therapeutic targets in non-small cell lung cancer.

Grace K Dy1, Alex A Adjei.   

Abstract

Over the last decade, systemic cancer therapies have evolved to exploit the growing knowledge of molecular aberrations involved in the development and progression of lung cancer. This review highlights the biological targets relevant in the treatment of non-small cell lung cancer.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19349491     DOI： 10.1513/pats.200808-099LC

Source DB:  PubMed          Journal:  Proc Am Thorac Soc        ISSN： 1546-3222


  9 in total

1.  Cabozantinib Loaded DSPE-PEG2000 Micelles as Delivery System: Formulation, Characterization and Cytotoxicity Evaluation.

Authors:  Qiuhong Yang; Ryan Moulder K; Mark S Cohen; Shuang Cai; Laird M Forrest
Journal:  BAOJ Pharm Sci       Date:  2015-01-05

2.  Andrographolide regulates epidermal growth factor receptor and transferrin receptor trafficking in epidermoid carcinoma (A-431) cells.

Authors:  Y Tan; K H Chiow; D Huang; S H Wong
Journal:  Br J Pharmacol       Date:  2010-02-19       Impact factor: 8.739

3.  Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies.

Authors:  Ramon Andrade de Mello; Dânia Sofia Marques; Rui Medeiros; António Mf Araújo
Journal:  World J Clin Oncol       Date:  2011-11-10

4.  Fetuin-A ({alpha}2HS-glycoprotein) is a major serum adhesive protein that mediates growth signaling in breast tumor cells.

Authors:  Amos M Sakwe; Rainelli Koumangoye; Shawn J Goodwin; Josiah Ochieng
Journal:  J Biol Chem       Date:  2010-10-18       Impact factor: 5.157

Review 5.  XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC.

Authors:  Ying Zhang; Fadila Guessous; Alex Kofman; David Schiff; Roger Abounader
Journal:  IDrugs       Date:  2010-02

6.  Src-mediated morphology transition of lung cancer cells in three-dimensional organotypic culture.

Authors:  Hong T Nguyen; Yan Zhuang; Lichun Sun; Steven P Kantrow; Jay K Kolls; Zongbing You; Ying Zhuo; Bin Shan
Journal:  Cancer Cell Int       Date:  2013-02-14       Impact factor: 5.722

Review 7.  Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer.

Authors:  C Zielinski; S Knapp; C Mascaux; F Hirsch
Journal:  Ann Oncol       Date:  2013-02-07       Impact factor: 32.976

8.  Predicting Survival in Patients with Advanced Non-squamous Non-small Cell Lung Cancer: Validating the Extent of Metastasis.

Authors:  Dong Soo Lee; Jin Hyoung Kang; Chang Geol Lee; Seoung Jun Kim; Young Jin Choi; Kyo Young Lee; Yeon Sil Kim
Journal:  Cancer Res Treat       Date:  2013-06       Impact factor: 4.679

9.  NVP-BEZ-235 enhances radiosensitization via blockade of the PI3K/mTOR pathway in cisplatin-resistant non-small cell lung carcinoma.

Authors:  Kwang Woon Kim; Carey J Myers; Dae Kwang Jung; Bo Lu
Journal:  Genes Cancer       Date:  2014-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.